Cultured cells of the murine lung carcinoma called line 1 express very low levels of H-2 class I antigens and are resistant to lysis mediated by alloreactive T cells. In order to investigate how the expression of class I antigens affects the in vivo growth of this spontaneous tumor, H-2DP genes were transferred into line 1 cells. Cloned transfectants that displayed H-2DP surface antigens were identified using flow cytometry. The transfected H-2DP antigens appeared normal by twodimensional gel electrophoresis and could also function as excellent targets for T-cell-mediated lysis in vitro. Marked differences in tumorigenicity (defined as tumor growth in immunologically competent hosts) were observed between the DP transfected cells and untransfected or control transfected line 1 cells in syngeneic mice only if the animals had previously received injections of irradiated DP transfectants. Expression of DP antigens did not appreciably affect the growth of line 1 tumors in immunologically naive syngeneic mice or necessarily cause rejection in allogeneic mice. Our in vivo results show that increased expression of class I antigens can reduce the growth of tumors like line 1 that lack all class I antigens. Our results also suggest that increasing class I antigens alone on some spontaneous tumors deficient in expression will not by itself be sufficient for tumor rejection.
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ly, in the T10-sarcoma system it was suggested that the expression of the Dk gene product actually enhanced the metastatic ability of these cells (11) . Thus, it is of particular interest to examine the role of H-2D region genes in tumor growth.
In this report, we use transfection of an H-2DP gene to evalUate how expression of class I antigens affects the tumor growth of a spontaneous BALB/c lung carcinoma called line 1 (15) . The DP gene is one of a variety of genomic clones that have been isolated and encode fully functional class I MHC molecules upon transfection into mouse L cells (16, 17) . Line 1 cells provide an excellent system to study the role of class I expression in tumor growth because they are markedly deficient in expression of all class I MHC antigens (H-2K, H-2D, H-2L, and TL) by flow cytometry (ref. 18 and unpublished data), and are not normally susceptible to CTLmediated lysis in vitro (19) . In addition, line 1 cells resemble human small cell lung carcinoma cells (20) and embryonal carcinoma cells in MHC expression (21) and thus may be a good model for these tumors.
MATERIALS AND METHODS
Class I major histocompatibility complex (MHC) antigens (classically H-2K, H-2D, and H-2L in the mouse) function as major transplantation antigens during graft rejection and as restriction elements for T lymphocytes during the recognition of other antigens (1) . Specifically, recognition of non-MHCencoded molecules by cytotoxic T lymphocytes (CTL) depends on the surface expression of both the appropriate target-specific and MHC antigens. Limiting quantities of either type of antigen can prevent effective cell lysis (2) .
There are a number of studies in which the ability to form tumors, or the aggressiveness of tumors, appears to be inversely correlated to the expression of class I antigens (3-12, for review see ref. 10 ). However, in many of these studies it is difficult to assign the altered tumorigenicity of these cells solely to the expression of class I molecules. More recently, gene transfection has been used to study the effect of class I expression in the methylcholanthrene-induced T10 tumor system (7) and in the AKR leukemia (9) and adenovirus systems (8) .
Intriguingly, some studies have also shown that class I antigen expression positively correlates with tumor growth. In one study, mouse lymphoma cells selected for loss of H-2 antigen expression Were less capable of forming tumors than were the parental H-2 class I-expressing cells (12) . Even more interesting was the observation that a gene, later shown to be encoded in the H-2D gene region (13, 14) , was dramatically elevated in a variety of tumor cells (3) . SimilarCell Lines. The BALB/c line 1 lung carcinoma was maintained in tissue culture as described (22) . The cloned lines described in this report were negative for all 12 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
tion, 10 ml of culture medium were added to the cells, and 8 hr later this was replaced by 15 ml of fresh culture medium. Selection of transfectants with 400 ug of Geneticin (G418, GIBCO) per ml was initiated following 36 hr of additional culture (26) .
Flow Cytometric, Immunological, and Biochemical Analyses. The DP-specific monoclonal antibody 7-16.10 (27) was obtained from J. A. Frelinger. The Dd-specific monoclonal antibody AF4-62.4 and the Kk-specific monoclonal antibody AF3-12.1 have been described (18) . Cells were stained for H-2 antigens using a two-step immunofluorescence technique (18) , and average densities of fluorescently labeled antigens were calculated as described (18) . The H-2P-reactive CTL were generated by culturing 2.5 x 107 BALB/c spleen cells (H-2d) with 1.25 x 107 irradiated P/J spleen cells (H-2P) using the above media (19) . The chromium release assays (19) and the two-dimensional gel electrophoresis (28) were done as previously described and are described in the figure legends.
RESULTS
Line 1 Transfectants Express Di Molecules. The F12 plasmid containing an H-2DP genomic clone was cotransfected into line 1 cells along with pko-neo, a plasmid that carries the neomycin resistance gene (neo). Approximately orne per 104 starting cells containing functional neo copies were obtained by selection in media containing G418. Four of the fifty G418-resistant colonies that were screened by flow cytometry contained cells reacting with the DP antibody 7-16. 10 , and clones that expressed DP were subsequently obtained by limiting dilution. Fig. 1 shows typical fluorescence histograms for one positive clone, C1.2, after staining with anti-Kk (control) and anti-DO antibodies. All of the transfectants stably expressed the DU gene product, although at a density significantly lower than normal spleen cells. Two of the three cloned transfectants used in this report, C1.2 and C1.6, were chosen because they expressed the highest constitutive levels of DP and the other, C13.10, because it expressed a lower but detectable level of the DP antigen.
Transfected H-2 Genes Produce Normal DP Proteins. Because a major goal of this report was to evaluate recognition of the transfectants in syngeneic hosts, it was necessary to establish that the transfected H-2 genes produced normal DP antigens. To this end, biosynthetically [35S]methioninelabeled DP molecules were immunoprecipitated from Nonidet P-40 extracts of transfectants or normal P/J spleen cells and analyzed by two-dimensional gel electrophoresis followed by fluorography (28) . The DP molecules isolated from the transfected line 1 cells are identical to those isolated from P/J spleen cells, as shown by the representative autoradiographs in Fig. 2 . Thus, by the technique of two-dimensional gel analysis no abnormality was observed in the transfected DP gene product.
Alloreactive T Cells Specifically Lyse Line 1 DP Transfectants in Vitro. In order to demonstrate that the DP on the transfectants was functional, we compared the lysis of DP ttansfectants and control cells by cytotoxic T lymphocytes with specificity for H-2P antigens using a standard in vitro 51Cr release assay (Fig. 3) . Lysis of the DP transfectants by the DP-specific cytotoxic T-cell population was comparable in magnitude to lysis of P/J spleen blast cells that express high levels of H-2P class I antigens. In contrast, lysis of the DP-negative target cells was much lower. Irrelevant BALB/c anti-C3H effectors did not lyse the transfected or untrans- ments do not directly demonstrate that the DP molecules can serve as class I self-restriction elements, they do indicate that T cells can recognize the DP antigens and specifically lyse cells expressing this antigen. DP Line 1 Transfectants Can Be Recognized in Vivo as Allografts. To evaluate whether DP antigens expressed by line 1 transfectants could be recognized in vivo, line 1, Neo-1, C13.10, C1.2, and C1.6 cells were transplanted into groups of BALB/c mice, and tumor size was followed over time (Fig.  4) . The growth of the neo-only transfected cells (Neo-1) in BALB/c mice was virtually identical to the growth of untransfected line 1 cells, and within 2 weeks after receiving 5000 Neo-1 cells large tumors were present in all five mice. It was expected that the DP antigens on the transfectants would elicit a strong allogeneic reaction that would lead to rejection of the 5000-cell inocula. Results using C1.6 and C13.10 cells were in agreement with our expectations (Fig. 4) (29) from BALB/c mice also still expressed the DP class 1 antigen suggesting we are not seeing antigenic modulation. Furthermore, C1.2 cells are capable of being rejected, as BALB/c mice primed with P/J spleen cells 4 and 2 weeks before challenge can reject an inoculum ofat least 5000 C1.2 cells-suggesting the DP molecule is still present (Fig.  4) . DP were challenged with line 1, Neo-1, C1.2, C1.6, or C13.10 cells, and tumor size was followed over time (Fig. 5) . The primed mice received irradiated C1.6 cells prior to tumor challenge as described above. With an inoculum of 5000 cells, all DP transfectants and controls (line 1 and Neo-1) produced tumors in unprimed mice, although perhaps at slightly different rates. When primed mice were used, the DPtransfected line 1 cells were significantly less tumorigenic than control cells. With one exception, none of the primed mice developed tumors when challenged by any of the transfectants. Similar results were obtained with inocula of 500 and 50,000 cells, the only difference being the time required for tumors to reach a specific size (data not shown). These data strongly suggest that the expression of class I antigens can dramatically lower the growth of line 1 tumor cells in syngeneic hosts.
DISCUSSION
We have shown that transfection of H-2DP genes into line 1 cells dramatically decreases the ability of this tumor to grow in (BALB/c x P/J)F1 mice. The simplest interpretation of these results is that the decreased tumorigenicity of the DP transfectants results from increased expression of H-2 class 1 antigens and their recognition by T cells. Previous studies had suggested that the expression of the D region gene actually enhanced the ability of transformed cells to grow as tumors. In the T10 system, the ability to grow as metastatic tumors correlated with the expression of the Dk antigen (11) . Transfection of the Kk gene into these cells reduced their ability to grow as tumors and metastasize, but transfection of the Dk gene was not reported (7) . Even more striking was the report that the expression of a D region gene was a general feature of oncogenesis in the mouse (3, 13) . In light of these reports, it is significant that the expression of a D region gene in line 1 cells can lead to reduced tumor growth.
In contrast to other reports describing the malignancy of tumor cells transfected with class I genes (7) (8) (9) (39) . Such a mechanism may also be operating in both the methylcholanthrene-induced T10 sarcoma system and the AKR K36 leukemia system (9, 11), which lack one or more class I antigens. Consistent with this mechanism is that the transfection and expression of Kk class I gene can cause the reduced growth of these tumors (9, 11) . Finally, tumors may also represent the clonal expansion of cells that normally lack class I antigens. Such cells seem to be normally present in a number oftissues (4, 40, 41) Even the expression of a strong transplantation class I antigen by itself is not always sufficient for tumor rejection.
Our unexpected results with the growth ofthe DP transfectant C1.2 in BALB/c mice were interesting in that they showed that surface expression of foreign class I molecules does not necessarily lead to an effective allograft rejection response. This could not be explained by a low level of DP antigens because clone C1.6, which expresses the same density of DP as does C1.2, was easily rejected. A similar result was obtained in the Sal tumor line in which allogeneic MHC class I antigen expression was insufficient for tumor rejection (S. Ostrand-Rosenberg, personal communication). Perhaps the growth of C1.2 is due to a suppressive effect as seen in the ultraviolet-induced fibrosarcoma system (42), the activation of oncogenes, or because of a yet unknown mechanism.
Using recombinant DNA techniques we showed that the deficient expression of class I molecules can contribute to the tumorigenicity of a lung carcinoma. This is particularly interesting because the most common human malignancy associated with deficient class I antigen expression is small cell lung carcinoma (20) . Human small cell carcinoma cells, like line 1 cells, express little or no class I antigens due to the low levels of f32-microglobulin and class I mRNA (ref. 20 and unpublished data). Further, the expression of these class I antigens on both the human tumor and line 1 cells can be induced with y-interferon treatment. Because of these similarities, line 1 may serve as an animal model for this class of human tumors. Society. This work was supported by Research Grants CA 28332 and CA 41448 from the National Institutes of Health. This is publication 22 from the Immunology Unit of the University of Rochester Cancer Center.
